Nanhai Longtime Pharmaceutical Co., Ltd.
Founded in 2003, Nanhai Longtime Pharmaceutical Co., Ltd. is the industrialization base of the national first-class new drug “ recombinant human basic fibroblast growth factor（Gaifu)”. Gaifu is clinically used for the treatment of trauma, surgical wounds, burns and ulcers, etc., producing significant therapeutic effects. It is a first-line medication recommended by Clinical Guideline. Over the years, it has won many national awards, such as the Second Prize of National Award for Technological Invention and the First Prize of National Science and Technology Progress Award.
According to incomplete statistics, there are more than 10 million trauma patients every year in the world, and the number of deaths caused by trauma each year exceeds 5 million, accounting for 8.8% of the global death toll. Trauma ranks third among the causes of death, second only to cardiovascular diseases and tumors, and has become the leading cause of death among people under 45 years old. Great efforts have been made to prevent and reduce the social harm caused by trauma and effectively reduce the traumatic disability and mortality. The national first-class new drug “recombinant human basic fibroblast growth factor for external use” (Gaifu) is one of the masterpieces created by Nanhai Longtime Pharmaceutical Co., Ltd., specifically for the treatment of wounds and ulcers.
The birth and development of Nanhai Longtime Pharmaceutical Co., Ltd. originated from the industry-university-research cooperation project titled “High-tech Industrialization Demonstration Project for National First-Class New Drug Recombinant Human Basic Fibroblast Growth Factor for External Use”. In 2003, this project was successfully implemented in the Nanhai Core Park of Foshan National High-tech Industrial Development Zone, which marked the official birth of the company. Afterwards, with the continuous advancement, deepening and expansion of the project, it has been listed as the national, provincial and ministerial science and technology project for 10 times, and won 5 awards at various levels, including the Second Prize of National Award for Technological Invention and the First Prize of National Science and Technology Progress Award. After years of unremitting efforts, the company has become a high-tech enterprise in Guangdong Province, Guangdong Cell Growth Factor Research and Development Engineering Technology Research Center, Guangdong Postdoctoral Innovation & Practice Base, and the world’s largest production base for bulk drug of recombinant human basic fibroblast growth factor.
Under the leadership of the founder Mr. Fu Tingling, the company has always adhered to the principle of “setting technology as priority”, and has long been committed to the research and development of products in the field of trauma repair. The product range covers biopharmaceuticals, medical apparatus and medical cosmetics and so on. The company’s leading product, the national first-class new drug “recombinant human basic fibroblast growth factor for external use” (Gaifu) is one of the nine genetic engineering drugs with independent intellectual property rights in China. It is a key scientific and technological project of the National 8th, 9th and 10th Five-Year Plan and key achievement of the National 863 Program. The technological level of this product has reached the world’s leading level. It has been widely used in the field of trauma repair (such as trauma, burns, chronic skin ulcers, surgical operation, plastic surgery, national defense, etc.). It has been used to cure more than 100 million patients, and its significant therapeutic effect has been highly recognized by the majority of medical workers and patients. The company has signed the product exporting agreements with more than 10 countries. The company's skin care products “Liyun” and “Haiben” series products are complementary to each other online and offline, and are gradually becoming the mainstream brands in the beauty and skin care industry.
In order to build a first-class bio-pharmaceutical enterprise in China and even the whole world, the company has formulated a long-term strategic plan, and will continue to focus on the research and development of genetic engineering products, gradually form a complete set of industrial chain, always adhere to technological innovation, shoulder the responsibility of protecting the public health, strive to become the backbone force of China’s bio-pharmaceutical industry and create a new glory of bio-pharmaceutical industry.